AMPLIA THERAPEUTICS ORD
Amplia Therapeutics Launches New Narmafotinib Ovarian Cancer Study with ANZGOG
Amplia Therapeutics launches PRROSE trial with narmafotinib and ANZGOG in ovarian cancer; 15–20 patients, safety focus, biomarker data.
Amplia Therapeutics Halts AMPLICITY Trial Recruitment After Chemo-Related DLTs
Amplia Therapeutics halts AMPLICITY recruitment after DLTs with narmafotinib mFOLFIRINOX; pivots to new combos, delaying readouts and raising investor risk.
Amplia Therapeutics Reports Stronger Efficacy and Survival in Pancreatic Cancer Trial
Amplia Therapeutics reports ACCENT trial: 7.8% CR, 35.9% ORR, 11.1-month median OS in pancreatic cancer; trading halt ahead of AACR.
Amplia Therapeutics Releases New Topline Data from ACCENT Narmafotinib Pancreatic Cancer Trial
Amplia Therapeutics (ASX: ATX) has released new topline data from an ongoing trial of its best-in-class selective FAK inhibitor narmafotinib on advanced pancreatic cancer. The ACCENT clinical trial is investigating the safety, tolerability, pharmacokinetics and preliminary efficacy of narmafotinib when used in combination with standard-of-care chemotherapies gemcitabine and Abraxane. Latest data to 20 July has […]
